Basit öğe kaydını göster

dc.contributor.authorKantarci, Fatih
dc.contributor.authorMihmanli, I.
dc.contributor.authorÇelik, Oğuz Cem
dc.contributor.authorGazioglu, N.
dc.contributor.authorKadioglu, Pinar
dc.contributor.authorBoysan, S. N.
dc.date.accessioned2021-03-03T07:39:37Z
dc.date.available2021-03-03T07:39:37Z
dc.date.issued2012
dc.identifier.citationBoysan S. N. , Kantarci F., Çelik O. C. , Mihmanli I., Gazioglu N., Kadioglu P., "Atherosclerotic Risk Factors and Premature Atherosclerosis in Acromegaly Before and After 48 Months of Octreotide-LAR Treatment", ANGIOLOGY, cilt.63, sa.7, ss.522-527, 2012
dc.identifier.issn0003-3197
dc.identifier.otherav_132616b1-20aa-4dff-81e6-66358907ae4c
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/18328
dc.identifier.urihttps://doi.org/10.1177/0003319711431879
dc.description.abstractWe studied premature atherosclerosis with carotid Doppler ultrasonography in active acromegaly before and after treatment. Patients (n = 27) with active acromegaly and 12 age-, gender-, and body mass index-matched healthy individuals were included in the study. Carotid intima-media thickness was decreased significantly in the inactive group after treatment (median: 0.6 mm, interquartile range [IQR]: 0.55-0.80]) when compared with the active group (median: 0.9 mm [IQR: 0.75-1.15], P < .0001), but there was no significant difference between the inactive and control groups. There was a correlation between homeostasis model of assessment-insulin resistance (P = .01, r = .41) and growth hormone (GH; P < .0001, r = .46). In conclusion, premature atherosclerosis was demonstrated in active acromegaly patients probably as a consequence of insulin resistance and direct vascular effects of GH and/or insulin-like growth factor 1.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.subjectPERİFERAL VASKÜLER HASTALIĞI
dc.subjectKlinik Tıp
dc.subjectTıp
dc.titleAtherosclerotic Risk Factors and Premature Atherosclerosis in Acromegaly Before and After 48 Months of Octreotide-LAR Treatment
dc.typeMakale
dc.relation.journalANGIOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume63
dc.identifier.issue7
dc.identifier.startpage522
dc.identifier.endpage527
dc.contributor.firstauthorID1481


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster